Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
Pt
CAS Number:
Molecular Weight:
195.08
NACRES:
NA.23
PubChem Substance ID:
UNSPSC Code:
12141734
MDL number:
InChI
1S/Pt
SMILES string
[Pt]
InChI key
BASFCYQUMIYNBI-UHFFFAOYSA-N
assay
99.95%
form
tubes
manufacturer/tradename
Goodfellow 498-125-10
resistivity
10.6 μΩ-cm, 20°C
L × wall thickness
100 mm × 0.1 mm
O.D. × I.D.
3.0 mm × 2.8 mm
bp
3827 °C (lit.)
mp
1772 °C (lit.)
density
21.45 g/cm3 (lit.)
Related Categories
General description
For updated SDS information please visit www.goodfellow.com.
Legal Information
Product of Goodfellow
Storage Class
13 - Non Combustible Solids
wgk
nwg
flash_point_f
Not applicable
flash_point_c
Not applicable
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Fausto Petrelli et al.
Lung cancer (Amsterdam, Netherlands), 81(3), 337-342 (2013-07-31)
The sole agents pemetrexed (PEM), docetaxel and anti-EGFR agents are approved second-line therapies for non-small cell lung cancer (NSCLC) after failure with cisplatin-based doublets. The potential usefulness of platinum-based doublets as rechallenge for second-line chemotherapy has not yet been established.
Thorsten Langer et al.
Trends in pharmacological sciences, 34(8), 458-469 (2013-06-19)
Childhood cancer survival rates are now nearly 80% in more developed European countries because of improved therapies and better supportive care. Platinum chemotherapy drugs, such as cisplatin and carboplatin, are the cornerstone of many effective therapeutic protocols for childhood cancer.
Combination therapy: histone deacetylase inhibitors and platinum-based chemotherapeutics for cancer.
Himashinie V K Diyabalanage et al.
Cancer letters, 329(1), 1-8 (2012-10-04)
One of the most promising strategies to increase the efficacy of standard chemotherapy drugs is by combining them with low doses of histone deacetylases inhibitors (HDACis). Regarded as chemosensitizers, the addition of well-tolerated doses of HDACis to platinum-based chemotherapeutics has
Hai-Bo Wei et al.
Chinese medical journal, 125(16), 2902-2907 (2012-08-31)
Platinum-based regimens are used as standard first-line chemotherapy in non-small cell lung cancer (NSCLC) patients. To study if pharmacogenetic approach may allow a tailored selection of platinum chemotherapy for advanced NSCLC, we performed a meta-analysis to compare chemosensitivity to platinum
Xiao-yong Shen et al.
PloS one, 8(8), e69553-e69553 (2013-08-14)
X-ray repair cross-complementing protein 3 (XRCC3) is an essential gene involved in the double-strand break repair pathway. Published evidence has shown controversial results about the relationship between XRCC3 Thr241Met polymorphism and clinical outcomes of non-small cell lung cancer (NSCLC) patients
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service